Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR-0215 in adults with hereditary angioedema
ISRCTN99457796Phase 2Completed
- Sponsor
- Astria Therapeutics
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of navenibart in hereditary angioedema (HAE) (3 arms), sponsored by Astria Therapeutics. Primary endpoint: Number of participants experiencing treatment-emergent adverse events. Started Feb 2023; status: completed.
02
Drugs
navenibart
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on ISRCTN99457796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN99457796.